NUVARING Drug Patent Profile
✉ Email this page to a colleague
When do Nuvaring patents expire, and what generic alternatives are available?
Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA.
The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nuvaring
A generic version of NUVARING was approved as ethinyl estradiol; etonogestrel by TEVA PHARMS USA INC on January 13th, 2021.
Summary for NUVARING
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 28 |
Patent Applications: | 208 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NUVARING |
Drug Sales Revenues: | Drug sales revenues for NUVARING |
What excipients (inactive ingredients) are in NUVARING? | NUVARING excipients list |
DailyMed Link: | NUVARING at DailyMed |



Recent Clinical Trials for NUVARING
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Lupin Research Inc | Phase 2 |
Andrea Roe, MD, MPH | Phase 4 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 |
Pharmacology for NUVARING
Drug Class | Estrogen Progestin |
Mechanism of Action | Estrogen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for NUVARING
Paragraph IV (Patent) Challenges for NUVARING
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NUVARING | Vaginal Ring | ethinyl estradiol; etonogestrel | 0.015 mg/24 hour 0.12 mg/24 hour | 021187 | 1 | 2013-06-17 |
US Patents and Regulatory Information for NUVARING
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NUVARING
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NUVARING
See the table below for patents covering NUVARING around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 325774 | See Plans and Pricing | |
Israel | 123813 | DRUG DELIVERY SYSTEM FOR TWO OR MORE ACTIVE SUBSTANCES | See Plans and Pricing |
Turkey | 9800648 | See Plans and Pricing | |
Hong Kong | 1016886 | See Plans and Pricing | |
Russian Federation | 2206325 | СИСТЕМА ДОСТАВКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ДЛЯ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ ВЕЩЕСТВ (DRUG DELIVERY SYSTEM FOR TWO OR MORE ACTIVE SUBSTANCES) | See Plans and Pricing |
Australia | 6075198 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NUVARING
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1453521 | CA 2016 00016 | Denmark | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
1214076 | C01214076/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
1380301 | CA 2009 00017 | Denmark | See Plans and Pricing | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
0398460 | C300221 | Netherlands | See Plans and Pricing | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
0771217 | 07C0001 | France | See Plans and Pricing | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
1453521 | 300814 | Netherlands | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |